In 2021, the Global Inflammatory Bowel Disease Treatment market was worth around US$ 19.3 Billion. With the increasing expenditure incurred on Inflammatory Bowel Disease Treatment worldwide, the market is expected to reach a worth of about US$ 35.1 Billion by the end of 2032, with a projected CAGR of 5.7% from 2022 to 2032. From 2017 to 2021, the Inflammatory Bowel Disease Treatment Market experienced a growth of 4.7%.
Attributes | Details |
---|---|
Global Inflammatory Bowel Disease Treatment Market Size (2021) | US$ 19.3 Billion |
Global Inflammatory Bowel Disease Treatment Market Size (2022) | US$ 20.2 Billion |
Projected Market Value (2032) | US$ 35.1 Billion |
Global Market Growth Rate (2022 to 2032) | 5.7% CAGR |
United States Growth Rate (2022 to 2032) | 6.4% CAGR |
Share of Top 5 Countries | 61% |
Key Companies Profiled |
|
Inflammatory Bowel Disease can occur at any age, although the disease is most common in adolescents and adults between the ages of 15 and 35. Diet and Stress do not cause inflammatory bowel disease but they can worsen the conditions. According to some recent research, hereditary, genetic, and environmental factors contribute to the disease’s development.
According to a 2019 estimate from the Crohn's and Colitis Foundation, 1.6 million Americans have inflammatory bowel disease. In addition, the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) estimates that in 2020, there were about 3.4 million people in Europe who have IBD of some kind. IBD is affecting more and more people, which increases the need for efficient treatment solutions.
In the forthcoming years, the Inflammatory Bowel Disease Treatment market is expected to expand due to the rising use of biologics for the treatment of inflammatory bowel disease and the release of potent pipeline medications including Risankizumab, Ustekinumab, Tofacitinib, and upadacitinib.
In the upcoming years, the Inflammatory Bowel Disease Treatment market expansion is expected to be boosted by an increase in initiatives taken by various organizations to address the difficulties in the creation of novel therapies. For instance, the Crohn's and Colitis Foundation published a five-year plan in May 2019 to identify gaps in IBD research, development, and care. Additionally, the European Chronic Disease Alliance has made a lot of efforts to enhance the quality of life for people with inflammatory bowel disease.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
North America holds the largest Inflammatory Bowel Disease Treatment market. In 2021, North America contributed to around 40% of the global revenue. As of 2019, there were 730 clinical trials for IBD, including drug development, observational studies, and others, according to the USA National Library of Medicine. Of these, 268 clinical trials were carried out only in the USA.
A substantial portion of the IBD market in North America is held by Canada. The number of Canadians with IBD is almost around 300,000. It is anticipated that treating Canadians with IBD will cost US$ 1.28 Billion each year. The Quebec government launched a biosimilars initiative in 2021, according to announcements made by the minister of health and social services, Christian Dubé, patients will transition from original biologic medications to their biosimilar equivalents.
Besides, Asia-Pacific accounts for a promising Inflammatory Bowel Disease Treatment market. This is mainly due to the growing access to healthcare, increasing per capita medical expenditure, and rise in the number of patients with inflammatory bowel disease. The commonness of inflammatory bowel disease is higher in Asian countries including India, China, and Japan.
With 1.5 million IBD patients in 2020, India surpassed the USA as the nation with the most IBD patients. In India, only 3% of patients use biologics, a much lower percentage than in Western nations. Infliximab and Adalimumab, two biologics, have IBD approval in India. Since June 2020, Vedolizumab has also been approved.
A significant portion of all cases of inflammatory bowel disease is seen in Japan. Only infliximab and Adalimumab are approved in Japan for the treatment of both UC and CD, and the USA Food and Drug Administration approved five biological drugs for the treatment of IBD in 2016.
The USA has the largest market for Inflammatory Bowel Disease Treatment, which is projected to reach a valuation of US$ 13.6 Billion by 2032. From 2017 to 2021, the Inflammatory Bowel Disease Treatment market in the USA grew at a CAGR of 4.7% and is expected to experience a CAGR of 6.4% in the next ten years. Between 2022 and 2032, the USA is expected to be a market with a US$ 6.2 Billion absolute dollar opportunity.
According to the Crohn's and Colitis Foundation (CCFA), the number of new cases of Inflammatory Bowel Disease reported in the USA each year exceeds 70,000. Infliximab, Adalimumab, Certolizumab Pegol, and Golimumab are the four anti-TNF medications that have been authorized for the treatment of IBD in the USA. Two anti-integrin biologics, Natalizumab and Vedolizumab, have been licensed for the treatment of IBD, and biosimilars for both anti-TNF medications have been created. In the USA, the biologic Stekinumab, which inhibits the cytokines IL-12 and IL-23, has been licensed for the treatment of Crohn's disease.
In 2021, China was the second-largest Inflammatory Bowel Disease Treatment Market after the USA. The market in the country is expected to reach a valuation of US$ 4.2 Billion by 2032. From the year 2017 to 2021 China’s Inflammatory Bowel Disease Treatment Market experienced a CAGR of 5.5% and is projected to see a similar CAGR of 6.8% in the next ten years. By 2032, China is expected to be an absolute dollar opportunity of US$ 2 Billion.
A huge portion of the population smokes in China owing to the country's rising industrialization and evolving lifestyle. The World Bank estimates that in 2016, 48.4% of all male smokers were in China. Smoking has a negative impact on both the small and large intestines, which raises the prevalence of IBD treatment in China.
Reistone Biopharma Co. Ltd., a Chinese biopharmaceutical company in the clinical stages, reported positive findings from a phase II clinical trial that assessed the safety and effectiveness of its drug candidate, SHR0302, an investigational selective Janus kinase type 1 (JAK1) inhibitor, for the treatment of moderate-to-severe ulcerative colitis. The trials are being carried out in various locations, such as China, the USA, and other countries. The company was considering launching a phase III clinical trial in 2021.
The market in the United Kingdom is expected to grow from US$ 842.5 Million in 2017 to reach a valuation of US$ 1.4 Billion by 2032. During the next 10 years, the market in the country is expected to grow at a CAGR of 4.6% to gross an absolute dollar opportunity of US$ 509 Million during the forecast period.
Crohn’s Disease is seen to be the most common Inflammatory Bowel Disease. Revenue through the treatment of Crohn’s Disease expanded at a CAGR of 5% from 2017 to 2021 and is projected to grow at a CAGR of 6% from 2022 to 2032.
In 2021, revenue from Crohn's Disease treatment outscored the management of Crohn's Disease 2021 with a market share close to 60 percent. That with the increase in cases has helped to authorize the use of more and more biologics in the marketplace for the treatment of Inflammatory Bowel Disease.
According to Crohn’s and Colitis Foundation, around 25% of patients with Crohn's disease in the USA are prescribed biologics. Moreover, the popularity of Crohn’s disease is about 319 per 100,000 population in North America, while in Europe it is about 322 per 100,000 population.
The Inflammatory Bowel Disease Treatment market is moderately competitive and has numerous players. The key companies operating in the Inflammatory Bowel Disease Treatment Market are AbbVie Inc., Biogen, Johnson & Johnson Services, Inc., Amgen Inc., UCB S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Pfizer Inc., and Eli Lilly. To secure a dominating position in the market making key players are focusing on introducing new products through collaborations and partnerships.
Some of the recent developments by the key providers of Inflammatory Bowel Disease Treatment are as follows:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global Inflammatory Bowel Disease Treatment Market was valued at US$ 20.2 Billion in 2022 and is expected to be a US$ 14.9 Billion absolute dollar opportunity by 2032.
Over the projected period, the Inflammatory Bowel Disease Treatment Market is expected to increase at a CAGR of 5.7%, reaching a value of US$ 35.1 Billion by 2032.
The Inflammatory Bowel Disease Treatment Market expanded at a CAGR of 4.7% from 2017 through 2021.
Crohn’s Disease is seen to be the most common Inflammatory Bowel Disease. Revenue through the treatment of Crohn’s Disease expanded at a CAGR of 5% from 2017 to 2021 and is projected to grow at a CAGR of 6% by 2032.
AbbVie Inc., Biogen, Johnson & Johnson Services, Inc., Amgen Inc., UCB S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Pfizer Inc., are some of the key players in the Inflammatory Bowel Disease Treatment Industry.
The USA, United Kingdom, China, Japan, and South Korea are expected to drive the most Inflammatory Bowel Disease Treatment.
1. Executive Summary | Inflammatory Bowel Disease Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2017 to 2021 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2022 to 2032 5.3.1. Crohn's Disease 5.3.2. Ulcerative Colitis 5.4. Y-o-Y Growth Trend Analysis By Type, 2017 to 2021 5.5. Absolute $ Opportunity Analysis By Type, 2022 to 2032 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug Case 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Drug Case, 2017 to 2021 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Case, 2022 to 2032 6.3.1. Amino salicylates 6.3.2. Corticosteroids 6.3.3. TNF inhibitors 6.3.4. IL inhibitors 6.3.5. Anti- integrin 6.3.6. JAK inhibitors 6.3.7. Other Drug Classes 6.4. Y-o-Y Growth Trend Analysis By Drug Case, 2017 to 2021 6.5. Absolute $ Opportunity Analysis By Drug Case, 2022 to 2032 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Route of Administration 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2017 to 2021 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2022 to 2032 7.3.1. Oral 7.3.2. Injectable 7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017 to 2021 7.5. Absolute $ Opportunity Analysis By Route of Administration, 2022 to 2032 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distribution Channel 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2017 to 2021 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2022 to 2032 8.3.1. Hospital Pharmacy 8.3.2. Retail Pharmacy 8.3.3. Online Pharmacy 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017 to 2021 8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022 to 2032 9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. Asia Pacific 9.3.5. Middle East and Africa(MEA) 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. USA 10.2.1.2. Canada 10.2.2. By Type 10.2.3. By Drug Case 10.2.4. By Route of Administration 10.2.5. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Type 10.3.3. By Drug Case 10.3.4. By Route of Administration 10.3.5. By Distribution Channel 10.4. Key Takeaways 11. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Type 11.2.3. By Drug Case 11.2.4. By Route of Administration 11.2.5. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Type 11.3.3. By Drug Case 11.3.4. By Route of Administration 11.3.5. By Distribution Channel 11.4. Key Takeaways 12. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. United Kingdom 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Type 12.2.3. By Drug Case 12.2.4. By Route of Administration 12.2.5. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Type 12.3.3. By Drug Case 12.3.4. By Route of Administration 12.3.5. By Distribution Channel 12.4. Key Takeaways 13. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.1.4. Malaysia 13.2.1.5. Singapore 13.2.1.6. Australia 13.2.1.7. Rest of Asia Pacific 13.2.2. By Type 13.2.3. By Drug Case 13.2.4. By Route of Administration 13.2.5. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Type 13.3.3. By Drug Case 13.3.4. By Route of Administration 13.3.5. By Distribution Channel 13.4. Key Takeaways 14. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of Middle East and Africa(MEA) 14.2.2. By Type 14.2.3. By Drug Case 14.2.4. By Route of Administration 14.2.5. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Type 14.3.3. By Drug Case 14.3.4. By Route of Administration 14.3.5. By Distribution Channel 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. United Kingdom 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2021 15.1.2.1. By Type 15.1.2.2. By Drug Case 15.1.2.3. By Route of Administration 15.1.2.4. By Distribution Channel 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2021 15.2.2.1. By Type 15.2.2.2. By Drug Case 15.2.2.3. By Route of Administration 15.2.2.4. By Distribution Channel 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2021 15.3.2.1. By Type 15.3.2.2. By Drug Case 15.3.2.3. By Route of Administration 15.3.2.4. By Distribution Channel 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2021 15.4.2.1. By Type 15.4.2.2. By Drug Case 15.4.2.3. By Route of Administration 15.4.2.4. By Distribution Channel 15.5. Rest of Latin America 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2021 15.5.2.1. By Type 15.5.2.2. By Drug Case 15.5.2.3. By Route of Administration 15.5.2.4. By Distribution Channel 15.6. Germany 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2021 15.6.2.1. By Type 15.6.2.2. By Drug Case 15.6.2.3. By Route of Administration 15.6.2.4. By Distribution Channel 15.7. United Kingdom 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2021 15.7.2.1. By Type 15.7.2.2. By Drug Case 15.7.2.3. By Route of Administration 15.7.2.4. By Distribution Channel 15.8. France 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2021 15.8.2.1. By Type 15.8.2.2. By Drug Case 15.8.2.3. By Route of Administration 15.8.2.4. By Distribution Channel 15.9. Spain 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2021 15.9.2.1. By Type 15.9.2.2. By Drug Case 15.9.2.3. By Route of Administration 15.9.2.4. By Distribution Channel 15.10. Italy 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2021 15.10.2.1. By Type 15.10.2.2. By Drug Case 15.10.2.3. By Route of Administration 15.10.2.4. By Distribution Channel 15.11. Rest of Europe 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2021 15.11.2.1. By Type 15.11.2.2. By Drug Case 15.11.2.3. By Route of Administration 15.11.2.4. By Distribution Channel 15.12. China 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2021 15.12.2.1. By Type 15.12.2.2. By Drug Case 15.12.2.3. By Route of Administration 15.12.2.4. By Distribution Channel 15.13. Japan 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2021 15.13.2.1. By Type 15.13.2.2. By Drug Case 15.13.2.3. By Route of Administration 15.13.2.4. By Distribution Channel 15.14. South Korea 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2021 15.14.2.1. By Type 15.14.2.2. By Drug Case 15.14.2.3. By Route of Administration 15.14.2.4. By Distribution Channel 15.15. Malaysia 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2021 15.15.2.1. By Type 15.15.2.2. By Drug Case 15.15.2.3. By Route of Administration 15.15.2.4. By Distribution Channel 15.16. Singapore 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2021 15.16.2.1. By Type 15.16.2.2. By Drug Case 15.16.2.3. By Route of Administration 15.16.2.4. By Distribution Channel 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2021 15.17.2.1. By Type 15.17.2.2. By Drug Case 15.17.2.3. By Route of Administration 15.17.2.4. By Distribution Channel 15.18. Rest of Asia Pacific 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2021 15.18.2.1. By Type 15.18.2.2. By Drug Case 15.18.2.3. By Route of Administration 15.18.2.4. By Distribution Channel 15.19. GCC Countries 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2021 15.19.2.1. By Type 15.19.2.2. By Drug Case 15.19.2.3. By Route of Administration 15.19.2.4. By Distribution Channel 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2021 15.20.2.1. By Type 15.20.2.2. By Drug Case 15.20.2.3. By Route of Administration 15.20.2.4. By Distribution Channel 15.21. Israel 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2021 15.21.2.1. By Type 15.21.2.2. By Drug Case 15.21.2.3. By Route of Administration 15.21.2.4. By Distribution Channel 15.22. Rest of Middle East and Africa(MEA) 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2021 15.22.2.1. By Type 15.22.2.2. By Drug Case 15.22.2.3. By Route of Administration 15.22.2.4. By Distribution Channel 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Type 16.3.3. By Drug Case 16.3.4. By Route of Administration 16.3.5. By Distribution Channel 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. AbbVie Inc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Biogen 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Johnson & Johnson Services, Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Amgen Inc. 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. UCB S.A. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Novartis AG 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Takeda Pharmaceutical Company Ltd. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Merck & Co., Inc. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Pfizer Inc. 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Lilly 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports